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S U M M A R Y
Background: Blood safety remains an issue of major concern in transfusion medicine in sub-Saharan
Africa. Blood-borne agents such as the human immunodeﬁciency virus (HIV), hepatitis B virus (HBV),
hepatitis C virus (HCV), and Treponema pallidum are among the greatest threats to blood safety for the
recipient. This study aimed to determine the seroprevalence and risk factors of HIV, HCV, HBV, and
syphilis infections among ﬁrst-time blood donors at the new hospital-based blood bank in Ede´a,
Cameroon.
Methods: We carried out a retrospective analysis of blood donor data recorded between December 2011
and May 2012 at the blood bank of the Ede´a Regional Hospital. Antibodies to HIV types 1 and 2 were
screened with the Determine and ImmunoComb tests. Hepatitis B surface antigen and antibodies to HCV
were detected using DIASpot test strips. Syphilis was diagnosed using the Venereal Disease Research
Laboratory (VDRL) test and the Treponema pallidum hemagglutination assay (TPHA).
Results: A total of 543 blood donors were included, among whom 349 (64.3%) were family replacement
donors. One hundred and ﬁfteen donors (21.2%) were infected with at least one pathogen. The overall
seroprevalence rates of HIV, HBV, HCV, and syphilis were 4.1%, 10.1%, 4.8%, and 5.7%, respectively. We
found a total of 26 dual infections. The most common combinations were HBV–HCV and HBV–HIV. There
was a signiﬁcant association between HIV and HBV infections (adjusted odds ratio (aOR) 3.46, 95% CI
1.29–9.39; p = 0.014), and between HBV and HCV infections (aOR 2.81, 95% CI 1.02–10.12; p = 0.036).
Compared to voluntary donors, family replacement donors were signiﬁcantly more infected by at least
one screened pathogen (aOR 1.81, 95% CI 1.14–2.88; p = 0.013), and more infected speciﬁcally by HIV
(aOR 3.66, 95% CI 1.07–12.55; p = 0.039) and syphilis (aOR 2.81, 95% CI 1.05–7.46; p = 0.039).
Conclusions: Our ﬁndings indicate that blood safety remains a major problem in Cameroon where
hospital-based blood banks and family replacement donors are predominant. There is an urgent need for
a national blood transfusion program in Cameroon that will establish a nationally coordinated blood
transfusion service based on the principles of voluntary regular non-remunerated blood donation.
 2012 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Blood transfusion is an important therapeutic act that saves
millions of lives. It is estimated that more than 90 million blood
units are collected in the world each year.1 However, in spite of
the beneﬁts of blood transfusion, each transfused patient is at
risk of acquiring transfusion-transmissible infections (TTIs),* Corresponding author at: Internal Medicine Unit, Ede´a Regional Hospital, PO
Box 100, Ede´a, Cameroon. Tel.: +237 79644081.
E-mail addresses: noubiapjj@yahoo.fr, noubiapjj@gmail.com (J.J.N. Noubiap).
1201-9712/$36.00 – see front matter  2012 International Society for Infectious Disea
http://dx.doi.org/10.1016/j.ijid.2012.12.007principally the human immunodeﬁciency virus (HIV),
hepatitis B and C viruses (HBV and HCV), and Treponema
pallidum, the pathologic agent of syphilis. Transfusion of
contaminated blood has disastrous health consequences in
terms of morbidity and mortality due to acquired infections, and
this is associated with important economic losses incurred in
treating these patients who later become dependent and non-
productive. Although African countries actually face the greatest
demand for transfusion products in the world, and are the
countries where the prevalence of TTIs are highest, the blood
transfusion programs in these countries are equally the most
inadequate.2ses. Published by Elsevier Ltd. All rights reserved.
J.J.N. Noubiap et al. / International Journal of Infectious Diseases 17 (2013) e832–e837 e833To improve blood safety in Africa, the World Health Organiza-
tion (WHO) has adopted a strategy for Africa that aims to
implement a national policy for each African country by 2012, in
order to assure a safe and sufﬁcient blood supply. This strategy
includes the recruitment of regular, voluntary non-remunerated
blood donors, screening for all major TTIs in a quality controlled
manner, appropriate infrastructure, qualiﬁed personnel, and
ﬁnancial resources.3
In July 2011, the Ede´a Regional Hospital (ERH) was inaugurated
in the Littoral Region of Cameroon, and 4 months later a blood bank
was opened in this hospital. The aim of this study was to determine
the seroprevalence and risk factors of HIV, HCV, HBV, and syphilis
infections among ﬁrst-time blood donors at the new hospital-
based blood bank in Ede´a, Cameroon. This will serve as a baseline in
the monitoring of the prevalence of these TTIs in the population of
Ede´a, which will help in formulating strategies for improving blood
transfusion safety.
2. Materials and methods
2.1. Study design and setting
We conducted a retrospective analysis of blood donor data
recorded between December 2011 and May 2012 at the blood
bank of the ERH. Situated 66 km from Douala and 180 km from
Yaounde´, the respective economic and political capitals of
Cameroon, the ERH is the referral hospital for four health
districts that cover a total population estimated at 300 000
inhabitants. This hospital also has as its objective the manage-
ment of the numerous accidents along the Douala–Yaounde´ and
the Kribi–Ede´a highways, management which often requires
blood transfusions.
2.2. Study population
Donors were either volunteers, or relatives or friends of patients
who came to replace blood used or expected to be used by patients.
Voluntary donors either belonged to an association of blood donors
or came individually on their own account to donate blood.
Because the blood bank was new, they were almost exclusively
ﬁrst-time blood donors.
Donors were all apparently healthy subjects, aged between 18
and 65 years, weighing 50 kg or more, with a hemoglobin level
12.5 g/dl, and without serious illness, jaundice, sickle cell disease,
or current fever. The socio-demographic characteristics of the
selected donors were recorded in a database.
2.3. Sample collection
Blood samples were aseptically collected from each subject by
venipuncture in 5-ml red-top vacutainers (Becton Dickinson, NJ,
USA) and allowed to clot naturally at room temperature. Serum
specimens were separated by centrifugation at 3000 g for 5 min
and were used for the analyses.
2.4. HIV serology
HIV antibodies were detected by two rapid tests that detect
both HIV-1 and HIV-2 infections: the ImmunoComb HIV 1&2
BiSpot (Orgenics, Courbevoie, France), an indirect solid-phase
enzyme immunoassay that has a sensitivity of approximately
99.7% and a speciﬁcity of approximately 100%, and the Determine
HIV-1/2 (Abbott Laboratories, IL, USA), an immunochromato-
graphic assay that has a speciﬁcity of approximately 99.6% and a
sensitivity of approximately 99.4%. All samples positive by both
techniques were considered true positives, and those negative forboth methods were considered true negatives. All discordant
samples were excluded from the present analysis.
2.5. Hepatitis B surface antigenemia
HBV was detected using a one-step immunoassay-based
DIASpot HBsAg test kit (DIASpot Diagnostics, USA) for qualitative
detection of hepatitis B surface antigen (HBsAg) in serum. This test
has a relative sensitivity and speciﬁcity of 99% and 97.0%,
respectively.
2.6. HCV serology
IgG antibodies to HCV were detected using DIASpot HCV-Ab
test strips (DIASpot Diagnostics, USA), an immunochromato-
graphic assay that has approximately 99.9% sensitivity and
98.6% speciﬁcity.
2.7. Syphilis serology
Syphilis was diagnosed using the Venereal Disease Research
Laboratory (VDRL) test (Omega Diagnostic, UK) and the Treponema
pallidum hemagglutination assay (TPHA) test (Omega Diagnostic,
UK). Active syphilis was diagnosed if an individual’s blood tested
positive with both tests. All samples positive for one test and
negative for the other were excluded from the present analysis.
2.8. Statistical analysis
Data were coded, entered, and analyzed using SPSS version 17.0
(SPSS Inc., Chicago, IL, USA). The seroprevalences of HIV, HCV, HBV,
and syphilis were expressed in percentages of the entire study
group and by age, sex, and donor category. Odds ratios (OR) with
95% conﬁdence intervals (CI) were used to appreciate the impact of
different variables on HIV, HBV, HCV, and syphilis seropositivity.
We calculated the ORs by both univariate and multivariate logistic
regression analysis, with adjustments for age, gender, and type of
blood donor. p-Values of less than 0.05 were considered
statistically signiﬁcant.
2.9. Ethical considerations
In conformity with the procedure for blood donation imple-
mented at the blood bank of the ERH, all donors were informed that
their blood sample would be tested for TTIs and that the results
would be kept strictly conﬁdential. Pre- and post-test counseling
were subsequently done, and donors with positive results for any
of the TTIs were referred to medical doctors in charge of the
internal medicine unit for complementary work-up and appropri-
ate management.
Institutional authorization from the authorities at the ERH was
obtained prior to carrying out this study.
3. Results
Five hundred and forty-three donors were included in the
present analysis. Their ages ranged from 18 to 62 years, with a mean
age of 32.5  9.4 years. The male/female ratio was 4.5 (445/98). Of the
total donors, 35.7% (95% CI 31.7–39.9%, n = 194) were voluntary donors.
There was no signiﬁcant difference in age (p = 0.195) or gender
(p = 0.483) between family replacement and voluntary donors
(Table 1).
The overall seroprevalence rates of HIV, HBV, HCV, and syphilis
were 4.1% (95% CI 2.6–6.2%, n = 22), 10.1% (95% CI 7.8–13.1%,
n = 55), 4.8% (95% CI 3.2–7.0%, n = 26), and 5.7% (95% CI 4.0–8.1%,
n = 31), respectively. Of all donated blood during the study period,
Table 1
Socio-demographic characteristics of 543 ﬁrst-time blood donors in the Ede´a
Regional Hospital, Cameroon
Characteristics Number (%) 95% CI, %
Gender
Female 98 (18) 15.0–21.6
Male 445 (82) 78.4–85.0
Age group, years
20 30 (5.5) 3.8–7.9
21–30 236 (43.5) 39.3–47.8
31–40 171 (31.5) 27.6–35.6
41–50 77 (14.2) 11.4–17.5
>50 29 (5.4) 3.7–7.7
Type of donation
Volunteer 194 (35.7) 31.7–39.9
Family replacement 349 (64.3) 60.1–68.3
CI, conﬁdence interval.
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infection with at least one pathogen. Signiﬁcantly more family
replacement donors were seropositive for at least one of the
screened pathogens than voluntary donors (adjusted odds ratio
(aOR) 1.81, 95% CI 1.14–2.88; p = 0.013). Family replacement donors
were also signiﬁcantly more infected by HIV (aOR 3.66, 95% CI 1.07–
12.55; p = 0.039) and syphilis (aOR 2.81, 95% CI 1.05–7.46;
p = 0.039). The seroprevalence of syphilis was signiﬁcantly increased
in donors over 50 years of age (aOR 4.57, 95% CI 1.69–12.35;
p = 0.003). There were no other statistically signiﬁcant differences in
seroprevalence of these infections between age groups, males and
females, and types of donor (Tables 2–5).We found a total of 26 dual
infections. The most common dual infections were HBV-HCV and
HBV-HIV (Table 6). The risk of HIV-positive donors being positive for
HBV was statistically signiﬁcant (aOR 3.46, 95% CI 1.29–9.39;
p = 0.014), but this was not observed for syphilis (aOR 2.78, 95% CI
0.78–9.96; p = 0.102) or for HCV (OR 3.42, 95% CI 0.94–12.39;
p = 0.047; but no signiﬁcance after adjustment). The risk of HBV-
positive donors being positive for HCV was statistically signiﬁcant
(aOR 2.81, 95% CI 1.02–10.12; p = 0.036) (Table 6).
4. Discussion
One of the main recommendations of the WHO to achieve a safe
and sufﬁcient blood supply is the collection of blood from
voluntary regular non-remunerated donors who have a lower
risk of TTIs compared to family replacement and commercial
donors.3–5 Only 35.7% of donors in our study were voluntary non-
remunerated donors. This is far from the 80–100% voluntary
donations advocated by the WHO.3 In our study we found that
21.2% of the donated blood was seropositive for at least one of the
screened pathogens. This very high prevalence can be explained byTable 2
Relationship between socio-demographic characteristics and HBV seropositivity amon
Characteristics Total HBV-positive, n (%) O
Age group, years
20 30 3 (10) 0.
21–30 236 23 (9.7) 0.
31–40 171 19 (11.1) 1.
41–50 77 7 (9.1) 0.
>50 29 3 (10.3) 1.
Gender
Female 98 6 (6.1) 1.
Male 445 49 (11) 2.
Type of donor
Volunteer 194 17 (8.8) 1.
Family replacement 349 38 (10.9) 1.
OR, unadjusted odds ratio; aOR, adjusted odds ratio (each parameter is adjusted for the tw
the analysis (data not shown).the predominance of family replacement donors who were
signiﬁcantly more infected than voluntary donors (aOR 1.81,
95% CI 1.14–2.88; p = 0.013). Indeed, the seroprevalence of HIV and
syphilis were signiﬁcantly increased among family replacement
donors compared to voluntary donors (p = 0.039 for both HIV and
syphilis). This higher seroprevalence in family replacement donors
was also noted for HBV and HVC, though the differences were not
statistically signiﬁcant (p = 0.432 and p = 0.072, respectively).
These results, which are in keeping with those of other
studies,6–8 strongly indicate that family replacement donors are
less suitable for blood donation. These higher prevalence rates in
family replacement donors compared to voluntary donors could be
explained by the fact that people who voluntarily commit
themselves to regularly donate blood consider their blood safe,
because they do not have high-risk behaviors such as multiple sex
partners, intravenous drug abuse, or unprotected sexual inter-
course. On the contrary, a proportion of replacement donors, who
give blood because of urgent need, have these high-risk behaviors
and thus are more prone to be infected by these pathogens.
Although replacement blood donation is less safe, as shown by
Tapko et al. in many sub-Saharan African countries, family
replacement donors remain remarkably predominant, reaching
over 70% of blood donor populations in most instances.4 Much
more, in Africa 75–80% of the blood for transfusion still comes from
replacement hospital-based donors.5 The very high prevalence of
infected blood donors in our study calls for a more sensitive and
stringent screening of donated blood and for a major emphasis on
encouraging voluntary regular blood donation. As recommended
by the WHO,4 there is a need for a national blood transfusion
program in Cameroon that will ensure the quality, safety,
availability, and accessibility of blood transfusion within the
country.
In Cameroon, the prevalence of HIV in donated blood was
estimated at 8.2% in 2000.9 Accordingly, in 2003 Mbanya et al.
found a 7.9% prevalence of HIV among ﬁrst-time blood donors in
Yaounde´, Cameroon.10 The 4.1% prevalence found in our study
suggests that there may have been a decrease in the prevalence of
HIV in donated blood through this last decade. This could be a
result of the prevention programs that have been instituted in this
last decade. However the prevalence is still high, and the risk of HIV
infection through blood transfusion remains signiﬁcant in
Cameroon as in other African countries, since diagnostic methods
like the detection of the p24 antigen and viral genome screening,
which reduce the silent window period, are not regularly used in
Africa, except in South Africa, Egypt, and Ghana.5
Various seroprevalence rates of HBV have been reported in
African donors. The highest seroprevalence rates have been found
among donors in countries like Nigeria (18.6%),11 Guinea-Bissau
(16.2%),4 Mauritania (16.51%),4 Burkina Faso (14.96%),12 Senegalg 543 ﬁrst-time blood donors in the Ede´a Regional Hospital, Cameroon
R (95% CI) p-Value aOR (95% CI) p-Value
99 (0.29–3.36) 0.639 NS 0.981
94 (0.59–1.66) 0.840 NS 0.840
00
87 (0.38–2.00) 0.745 NS 0.745
03 (0.30–3.51) 0.580 NS 0.968
00
00 (0.79–4.57) 0.146 NS 0.146
00
27 (0.67–2.43) 0.432 NS 0.432
o others); CI, conﬁdence interval; NS, adjustments made no signiﬁcant difference to
Table 3
Relationship between socio-demographic characteristics and HCV seropositivity among 543 ﬁrst-time blood donors in the Ede´a Regional Hospital, Cameroon
Characteristics Total HCV-positive, n (%) OR (95% CI) p-Value aOR (95% CI) p-Value
Age group, years
20 30 2 (6.7) 1.46 (0.33–6.45) 0.428 NS 0.620
21–30 236 12 (5.1) 1.14 (0.52–2.51) 0.747 NS 0.747
31–40 171 5 (2.9) 1.00
41–50 77 5 (6.5) 1.47 (0.54–4.03) 0.303 NS 0.449
>50 29 2 (6.9) 1.51 (0.34–6.76) 0.411 NS 0.585
Gender
Female 98 5 (5.1) 1.00
Male 445 21 (4.7) 0.92 (0.32–2.87) 0.519 NS 0.872
Type of donor
Volunteer 194 5 (2.6) 1.00
Family replacement 349 21 (6) 2.42 (0.85–7.45) 0.072 NS 0.072
OR, unadjusted odds ratio; aOR, adjusted odds ratio (each parameter is adjusted for the two others); CI, conﬁdence interval; NS, adjustments made no signiﬁcant difference to
the analysis (data not shown).
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found in our study is similarly high. This seroprevalence is almost
equal to the 10.7% found among ﬁrst-time Cameroonian donors by
Mbanya et al. in Yaounde´ in 2003,10 indicating that the burden of
hepatitis B has not decreased in Cameroon through this last
decade. Our ﬁndings also point out that younger donors are almost
equally infected by HBV as older donors, indicating that there is a
young age at acquisition of HBV among these donors. The younger
age at acquisition of HBV is the most important predictor of the
chronic carrier state of the infection, which may lead to chronic
hepatitis, cirrhosis, and hepatocellular carcinoma.14,15 As hepatitis
B vaccination has recently been included in the Expanded Program
on Immunization in Cameroon, a decrease in hepatitis B prevalence
in the general population is expected in the next decades.
In our study, 4.8% of donors were positive for HCV antibodies.
This corresponds to the ﬁndings of Mbanya et al. who found exactly
a 4.8% prevalence of HCV among ﬁrst-time blood donors in 2003, in
Yaounde´, Cameroon.10 This indicates a probable constant trend in
the seroprevalence of HCV among blood donors in Cameroon.
Various seroprevalence rates of HCV among blood donors have
been reported in other African studies. In Mali, Diarra et al.
reported a seroprevalence of 13.9%;16 in Burkina Faso, Nagalo et al.
reported a seroprevalence of 8.69%;12 in Tanzania and Nigeria,
Matee et al. and Buseri et al. reported prevalence rates of 1.5% and
6%, respectively;11,17 in Mozambique, there was no HCV infection
among 679 blood donors.17 These seroprevalence rates are globally
higher than values ranging between 0% and 1.4% reported in USA
and Europe.18,19
HCV is typically transmitted through blood contact (e.g., blood
transfusion, invasive medical procedures, and intravenous drug
injection). As blood transfusion is a major route of transmission in
the African context, blood products safe from HCV should permit aTable 4
Relationship between socio-demographic characteristics and HIV seropositivity among
Characteristics Total HIV-positive, n (%) OR (9
Age group, years
20 30 0 (0) 1.06 
21–30 236 10 (4.2) 1.10 
31–40 171 6 (3.5) 1.00
41–50 77 5 (6.5) 1.83 
>50 29 1 (3.4) 0.84 
Gender
Female 98 3 (3.1) 1.00
Male 445 19 (4.3) 1.41 
Type of donor
Volunteer 194 3 (1.5) 1.00 
Family replacement 349 19 (5.4) 3.66 
OR, unadjusted odds ratio; aOR, adjusted odds ratio (each parameter is adjusted for the tw
the analysis (data not shown).constant reduction in the HCV prevalence and its consequences,
such as chronic hepatitis, liver cirrhosis, and hepatocellular
carcinoma.
Our ﬁndings in accordance with those of other African studies
indicate a decreasing trend in the seroprevalence of syphilis among
blood donors in some Africans countries. For example, this
seroprevalence has decreased in Cameroon from 14.4% in
200220 to 5.7% in our study; in Tanzania, from 12.7% in 1999 to
4.7% in 200617,21 and in Ghana, from 13.5% in 2002 to 4.7% in
2009.22,23 This decrease may be related to a positive effect of the
prevention programs against HIV, as syphilis is a sexually
transmitted disease. Moreover, the prevalence of syphilis found
in these African studies may have been increased by false-positive
results due to the detection of other treponemes that are endemic
in Africa, such as pian, be´jel, and pinta, which cannot be
differentiated from syphilis by serologic tests.24
With regard to the co-infections, there was a signiﬁcant
association between HIV and HBV. As shown by other studies,
this association could be due to the fact that these infections share
similar modes of transmission (predominantly blood and high-risk
sexual behaviors).11,25,26 Others studies have shown an association
between HIV and syphilis, due to the fact that they are sexually
transmitted and especially because syphilis has skin lesions that
promote the transmission of the HIV.27 The overall prevalence of
dual infections (4.8%) in our study is not insigniﬁcant.
We found a considerable male predominance (82%) in blood
donation in our setting, a trend observed in many African
countries.5 This male dominance may be explained by the fact
that in the African context there is a general belief that men are
healthier than women,28,29 and thus are more suitable for blood
donation. In addition, women are said to make monthly blood
donations to nature through their menstrual cycle. Other 543 ﬁrst-time blood donors in the Ede´a Regional Hospital, Cameroon
5% CI) p-Value aOR (95% CI) p-Value
(1.04–1.08) 0.279 NS 0.282
(0.47–2.60) 0.819 NS 0.881
(0.66–5.13) 0.189 NS 0.283
(0.11–6.45) 0.669 NS 0.752
(0.41–4.88) 0.417 NS 0.541
1.00
(1.07–12.55) 0.027 3.66 (1.07–12.55) 0.039
o others); CI, conﬁdence interval; NS, adjustments made no signiﬁcant difference to
Table 5
Relationship between socio-demographic characteristics and syphilis seropositivity among 543 ﬁrst-time blood donors in the Ede´a Regional Hospital, Cameroon
Characteristics Total Syphilis positive, n (%) OR (95% CI) p-Value aOR (95% CI) p-Value
Age group, years
20 30 1 (3.3) 0.62 (0.07–4.22) 0.477 NS 0.663
21–30 236 10 (4.2) 0.61 (0.28–1.33) 0.210 NS 0.179
31–40 171 8 (4.7) 1.00 1.00
41–50 77 6 (7.8) 1.49 (0.59–3.76) 0.267 NS 0.452
>50 29 6 (20.7) 5.10 (1.91–13.70) 0.004 4.57 (1.69–12.35) 0.003
Gender
Female 98 6 (6.1) 1.00
Male 445 25 (5.6) 0.91 (0.36–2.29) 0.846 NS 0.848
Type of donor
Volunteer 194 5 (2.6) 1.00 1.00
Family replacement 349 26 (7.4) 3.04 (1.15–8.06) 0.019 2.81 (1.05–7.46) 0.039
OR, unadjusted odds ratio; aOR, adjusted odds ratio (each parameter is adjusted for the two others); CI, conﬁdence interval; NS, adjustments made no signiﬁcant difference to
the analysis (data not shown).
Table 6
Associations in the occurrence of HIV, HCV, HBV, and syphilis among 543 ﬁrst-time blood donors in the Ede´a Regional Hospital, Cameroona
Characteristics n (%) OR (95% CI) p-Value aOR (95% CI) p-Value
HIV–HBV 6 (23.1) 3.61 (1.35–9.66) 0.007 3.48 (1.29–9.39) 0.014
HIV–HCV 3 (11.5) 3.42 (0.94–12.39) 0.047 NS 0.202
HIV–syphilis 3 (11.5) 2.78 (0.78–9.96) 0.102 NS 0.199
HBV–syphilis 4 (15.4) 1.34 (0.45–3.98) 0.386 NS 0.742
HBV–HCV 6 (23.1) 2.87 (1.10–7.47) 0.025 2.81 (1.07–7.39) 0.036
HCV–syphilis 4 (15.4) 3.30 (1.06–10.25) 0.054 3.22 (1.02–10.12) 0.045
OR, unadjusted odds ratio; aOR, odds ratio after adjusting for age, gender and type of donor; CI, conﬁdence interval; NS, adjustments for age, gender and type of donor made no
signiﬁcant difference to the analysis (data not shown).
a Total of dual infections: n = 26.
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restrict many women from donating blood.5
This study has some limitations, especially concerning the
accuracy of the diagnosis of HBV and HCV infections. We used
rapids tests which, in a recent international quality control of
blood-borne virus testing carried out in six African blood banks,
have been shown to have poor sensitivity compared to enzyme
immunoassays (EIAs) for the detection of HCV antibodies and
HBsAg.30 In terms of speciﬁcity, we did not perform conﬁrmatory
testing for anti-HCV- and HBsAg-positive samples, and therefore
we may have overestimated the prevalence of HBV and HCV
infections through the inclusion of some false-positives.
In conclusion, this high (21.2%) seroprevalence of TTIs in blood
donated at the ERH’s blood bank is alarming and indicates that
blood safety remains an issue of major concern in Cameroon, as in
other developing countries where hospital-based blood banks and
family replacement donors are predominant. There is an urgent
need for a national blood transfusion program in Cameroon that
will establish a nationally coordinated blood transfusion service
based on the principles of voluntary regular non-remunerated
blood donation.
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